Tech Company Financing Transactions
HepaRegeniX Funding Round
HepaRegeniX, operating out of Tübingen, secured $24.5 million in investment from Wellington Partners.
Transaction Overview
Company Name
Announced On
4/15/2025
Transaction Type
Venture Equity
Amount
$24,500,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to complete its ongoing Phase Ib trial and to advance the Phase IIa clinical trial for HRX-215, its lead clinical candidate in liver regeneration.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
Eisenbahnstraße 63
Tübingen, 72072
Germany
Tübingen, 72072
Germany
Phone
Website
Email Address
Overview
HepaRegeniX GmbH is a clinical stage company developing novel therapies for the treatment of acute and chronic liver diseases. Since its start in 2017, HepaRegeniX has successfully discovered and developed several drug candidates for the treatment of acute and chronic liver diseases based on a novel proprietary molecular target Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Operating Officer
Wolfgang Albrecht
Chief Scientific Officer
Birgit Jung
Browse more venture capital transactions:
Prev: 4/15/2025: QWERKY AI venture capital transaction
Next: 4/15/2025: Onfly venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to record every notable VC transaction. All VC database entries on this site are sourced from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs